CureVac N.V.

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, NOV.DE has a market cap of 139.5B. Regarding current trading prices, 5CV.F is priced at €3.91, while NOV.DE trades at €31.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas NOV.DE's P/E ratio is 10.19. In terms of profitability, 5CV.F's ROE is +0.18%, compared to NOV.DE's ROE of +0.61%. Regarding short-term risk, 5CV.F is less volatile compared to NOV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check NOV.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, VX1.DE has a market cap of 98.9B. Regarding current trading prices, 5CV.F is priced at €3.91, while VX1.DE trades at €385.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas VX1.DE's P/E ratio is 29.31. In terms of profitability, 5CV.F's ROE is +0.18%, compared to VX1.DE's ROE of +0.23%. Regarding short-term risk, 5CV.F is more volatile compared to VX1.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check VX1.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, DUL.DE has a market cap of 37.8B. Regarding current trading prices, 5CV.F is priced at €3.91, while DUL.DE trades at €279.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas DUL.DE's P/E ratio is 140.97. In terms of profitability, 5CV.F's ROE is +0.18%, compared to DUL.DE's ROE of +0.89%. Regarding short-term risk, 5CV.F is more volatile compared to DUL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check DUL.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 22UA.F has a market cap of 19.4B. Regarding current trading prices, 5CV.F is priced at €3.91, while 22UA.F trades at €77.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 22UA.F's P/E ratio is -16.39. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 22UA.F's ROE of -0.06%. Regarding short-term risk, 5CV.F is less volatile compared to 22UA.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check 22UA.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 0QF.F has a market cap of 17.1B. Regarding current trading prices, 5CV.F is priced at €3.91, while 0QF.F trades at €43.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 0QF.F's P/E ratio is -6.84. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 0QF.F's ROE of -0.30%. Regarding short-term risk, 5CV.F is less volatile compared to 0QF.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check 0QF.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, BM8.DE has a market cap of 11.8B. Regarding current trading prices, 5CV.F is priced at €3.91, while BM8.DE trades at €61.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas BM8.DE's P/E ratio is 88.51. In terms of profitability, 5CV.F's ROE is +0.18%, compared to BM8.DE's ROE of +0.09%. Regarding short-term risk, 5CV.F is less volatile compared to BM8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check BM8.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, EX9.DE has a market cap of 9.2B. Regarding current trading prices, 5CV.F is priced at €3.91, while EX9.DE trades at €32.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas EX9.DE's P/E ratio is 35.47. In terms of profitability, 5CV.F's ROE is +0.18%, compared to EX9.DE's ROE of +0.22%. Regarding short-term risk, 5CV.F is less volatile compared to EX9.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check EX9.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, BBZA.DE has a market cap of 2.7B. Regarding current trading prices, 5CV.F is priced at €3.91, while BBZA.DE trades at €48.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas BBZA.DE's P/E ratio is -5.60. In terms of profitability, 5CV.F's ROE is +0.18%, compared to BBZA.DE's ROE of -0.13%. Regarding short-term risk, 5CV.F is less volatile compared to BBZA.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check BBZA.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, MOR.DE has a market cap of 2.5B. Regarding current trading prices, 5CV.F is priced at €3.91, while MOR.DE trades at €67.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas MOR.DE's P/E ratio is -12.16. In terms of profitability, 5CV.F's ROE is +0.18%, compared to MOR.DE's ROE of -1.84%. Regarding short-term risk, 5CV.F is more volatile compared to MOR.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check MOR.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, BIO3.DE has a market cap of 1.6B. Regarding current trading prices, 5CV.F is priced at €3.91, while BIO3.DE trades at €32.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas BIO3.DE's P/E ratio is -51.43. In terms of profitability, 5CV.F's ROE is +0.18%, compared to BIO3.DE's ROE of -0.05%. Regarding short-term risk, 5CV.F is more volatile compared to BIO3.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check BIO3.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, BIO.DE has a market cap of 1.4B. Regarding current trading prices, 5CV.F is priced at €3.91, while BIO.DE trades at €41.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas BIO.DE's P/E ratio is -65.08. In terms of profitability, 5CV.F's ROE is +0.18%, compared to BIO.DE's ROE of -0.05%. Regarding short-term risk, 5CV.F is more volatile compared to BIO.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check BIO.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, IMU.DE has a market cap of 1.1B. Regarding current trading prices, 5CV.F is priced at €3.91, while IMU.DE trades at €5.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas IMU.DE's P/E ratio is -9.22. In terms of profitability, 5CV.F's ROE is +0.18%, compared to IMU.DE's ROE of -0.93%. Regarding short-term risk, 5CV.F is less volatile compared to IMU.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check IMU.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, NVV1.F has a market cap of 1.1B. Regarding current trading prices, 5CV.F is priced at €3.91, while NVV1.F trades at €6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas NVV1.F's P/E ratio is 3.11. In terms of profitability, 5CV.F's ROE is +0.18%, compared to NVV1.F's ROE of -5.46%. Regarding short-term risk, 5CV.F is less volatile compared to NVV1.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check NVV1.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, GBY.DE has a market cap of 884.7M. Regarding current trading prices, 5CV.F is priced at €3.91, while GBY.DE trades at €5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas GBY.DE's P/E ratio is -4.38. In terms of profitability, 5CV.F's ROE is +0.18%, compared to GBY.DE's ROE of -0.41%. Regarding short-term risk, 5CV.F is more volatile compared to GBY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check GBY.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 5CV.DE has a market cap of 879.5M. Regarding current trading prices, 5CV.F is priced at €3.91, while 5CV.DE trades at €3.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 5CV.DE's P/E ratio is 6.85. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 5CV.DE's ROE of +0.18%. Regarding short-term risk, 5CV.F is less volatile compared to 5CV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check 5CV.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 2EM.DE has a market cap of 586M. Regarding current trading prices, 5CV.F is priced at €3.91, while 2EM.DE trades at €11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 2EM.DE's P/E ratio is 34.38. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 2EM.DE's ROE of +0.20%. Regarding short-term risk, 5CV.F is more volatile compared to 2EM.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check 2EM.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, FYB.DE has a market cap of 335.1M. Regarding current trading prices, 5CV.F is priced at €3.91, while FYB.DE trades at €18.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas FYB.DE's P/E ratio is -1.96. In terms of profitability, 5CV.F's ROE is +0.18%, compared to FYB.DE's ROE of -0.39%. Regarding short-term risk, 5CV.F is less volatile compared to FYB.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check FYB.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 94E.F has a market cap of 331.6M. Regarding current trading prices, 5CV.F is priced at €3.91, while 94E.F trades at €5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 94E.F's P/E ratio is -5.48. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 94E.F's ROE of -0.84%. Regarding short-term risk, 5CV.F is more volatile compared to 94E.F. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check 94E.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 2VSA.F has a market cap of 325.8M. Regarding current trading prices, 5CV.F is priced at €3.91, while 2VSA.F trades at €4.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 2VSA.F's P/E ratio is -1.79. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 2VSA.F's ROE of -18.50%. Regarding short-term risk, 5CV.F is less volatile compared to 2VSA.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check 2VSA.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, VSC.DE has a market cap of 150.7M. Regarding current trading prices, 5CV.F is priced at €3.91, while VSC.DE trades at €2.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas VSC.DE's P/E ratio is -7.27. In terms of profitability, 5CV.F's ROE is +0.18%, compared to VSC.DE's ROE of -0.90%. Regarding short-term risk, 5CV.F is more volatile compared to VSC.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check VSC.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, HPHA.DE has a market cap of 135.2M. Regarding current trading prices, 5CV.F is priced at €3.91, while HPHA.DE trades at €2.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas HPHA.DE's P/E ratio is -3.18. In terms of profitability, 5CV.F's ROE is +0.18%, compared to HPHA.DE's ROE of -3.92%. Regarding short-term risk, 5CV.F is more volatile compared to HPHA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check HPHA.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, IF0.DE has a market cap of 129.9M. Regarding current trading prices, 5CV.F is priced at €3.91, while IF0.DE trades at €2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas IF0.DE's P/E ratio is -2.43. In terms of profitability, 5CV.F's ROE is +0.18%, compared to IF0.DE's ROE of -0.45%. Regarding short-term risk, 5CV.F is more volatile compared to IF0.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check IF0.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, GBM.F has a market cap of 102.3M. Regarding current trading prices, 5CV.F is priced at €3.91, while GBM.F trades at €1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas GBM.F's P/E ratio is -0.94. In terms of profitability, 5CV.F's ROE is +0.18%, compared to GBM.F's ROE of -0.80%. Regarding short-term risk, 5CV.F is less volatile compared to GBM.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check GBM.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 88Q.DE has a market cap of 87.5M. Regarding current trading prices, 5CV.F is priced at €3.91, while 88Q.DE trades at €5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 88Q.DE's P/E ratio is -4.96. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 88Q.DE's ROE of -0.75%. Regarding short-term risk, 5CV.F is more volatile compared to 88Q.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check 88Q.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, BNN.DE has a market cap of 52.9M. Regarding current trading prices, 5CV.F is priced at €3.91, while BNN.DE trades at €2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas BNN.DE's P/E ratio is -4.94. In terms of profitability, 5CV.F's ROE is +0.18%, compared to BNN.DE's ROE of -3.38%. Regarding short-term risk, 5CV.F is less volatile compared to BNN.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check BNN.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, C6O.DE has a market cap of 13.2M. Regarding current trading prices, 5CV.F is priced at €3.91, while C6O.DE trades at €0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas C6O.DE's P/E ratio is -0.05. In terms of profitability, 5CV.F's ROE is +0.18%, compared to C6O.DE's ROE of +1.21%. Regarding short-term risk, 5CV.F is less volatile compared to C6O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check C6O.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, GBMB.F has a market cap of 12.6M. Regarding current trading prices, 5CV.F is priced at €3.91, while GBMB.F trades at €0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas GBMB.F's P/E ratio is -0.08. In terms of profitability, 5CV.F's ROE is +0.18%, compared to GBMB.F's ROE of -0.80%. Regarding short-term risk, 5CV.F is more volatile compared to GBMB.F. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check GBMB.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, CNW.DE has a market cap of 6.5M. Regarding current trading prices, 5CV.F is priced at €3.91, while CNW.DE trades at €0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas CNW.DE's P/E ratio is -0.44. In terms of profitability, 5CV.F's ROE is +0.18%, compared to CNW.DE's ROE of -0.49%. Regarding short-term risk, 5CV.F is less volatile compared to CNW.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check CNW.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, LD6.F has a market cap of 4.5M. Regarding current trading prices, 5CV.F is priced at €3.91, while LD6.F trades at €0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas LD6.F's P/E ratio is -1.01. In terms of profitability, 5CV.F's ROE is +0.18%, compared to LD6.F's ROE of -3.29%. Regarding short-term risk, 5CV.F is less volatile compared to LD6.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check LD6.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, MDG1.DE has a market cap of 2M. Regarding current trading prices, 5CV.F is priced at €3.91, while MDG1.DE trades at €0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas MDG1.DE's P/E ratio is -0.11. In terms of profitability, 5CV.F's ROE is +0.18%, compared to MDG1.DE's ROE of -0.56%. Regarding short-term risk, 5CV.F is less volatile compared to MDG1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check MDG1.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, MDG1.F has a market cap of 397.9K. Regarding current trading prices, 5CV.F is priced at €3.91, while MDG1.F trades at €0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas MDG1.F's P/E ratio is -0.02. In terms of profitability, 5CV.F's ROE is +0.18%, compared to MDG1.F's ROE of -0.56%. Regarding short-term risk, 5CV.F is less volatile compared to MDG1.F. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check MDG1.F's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, T5O.DE has a market cap of 164.4K. Regarding current trading prices, 5CV.F is priced at €3.91, while T5O.DE trades at €0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas T5O.DE's P/E ratio is -0.25. In terms of profitability, 5CV.F's ROE is +0.18%, compared to T5O.DE's ROE of -1.91%. Regarding short-term risk, 5CV.F is less volatile compared to T5O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check T5O.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, AXP.DE has a market cap of 0. Regarding current trading prices, 5CV.F is priced at €3.91, while AXP.DE trades at €153.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas AXP.DE's P/E ratio is 59.63. In terms of profitability, 5CV.F's ROE is +0.18%, compared to AXP.DE's ROE of +0.05%. Regarding short-term risk, 5CV.F is more volatile compared to AXP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 5CV.F.Check AXP.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, MGNK.DE has a market cap of 0. Regarding current trading prices, 5CV.F is priced at €3.91, while MGNK.DE trades at €0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas MGNK.DE's P/E ratio is N/A. In terms of profitability, 5CV.F's ROE is +0.18%, compared to MGNK.DE's ROE of +4.09%. Regarding short-term risk, 5CV.F is less volatile compared to MGNK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check MGNK.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, CNWK.DE has a market cap of 0. Regarding current trading prices, 5CV.F is priced at €3.91, while CNWK.DE trades at €2.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas CNWK.DE's P/E ratio is -5.82. In terms of profitability, 5CV.F's ROE is +0.18%, compared to CNWK.DE's ROE of -0.86%. Regarding short-term risk, 5CV.F is less volatile compared to CNWK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check CNWK.DE's competition here

5CV.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 5CV.F stands at 879.5M. In comparison, 8CC1.DU has a market cap of 0. Regarding current trading prices, 5CV.F is priced at €3.91, while 8CC1.DU trades at €0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

5CV.F currently has a P/E ratio of 6.85, whereas 8CC1.DU's P/E ratio is N/A. In terms of profitability, 5CV.F's ROE is +0.18%, compared to 8CC1.DU's ROE of N/A. Regarding short-term risk, 5CV.F is less volatile compared to 8CC1.DU. This indicates potentially lower risk in terms of short-term price fluctuations for 5CV.F.Check 8CC1.DU's competition here